Fesoterodine is cost-effective relative to tolterodine and solifenacin for the treatment of overactive bladder with incontinence in Spain: results of an updated economic model

Angulo J1, Trocio J2, Snedecor S3, Kvasz M4, Rejas J5

Abstract Category

Epidemiology & Outcomes Research

Abstract 372
Non-Discussion Posters
Scientific Non Discussion Poster Session 29
1. Department of Urology, Hospital Universitario de Getafe, Getafe (Madrid), Spain, 2. Pfizer Inc., New York, NY, USA;, 3. Pharmerit North America LLC, Bethesda, MD, USA, 4. Pfizer Inc Europe, Paris, France, 5. Health Economics and Outcomes Research Department, Pfizer, S.L.U., Alcobendas (Madrid), Spain.
Links

Abstract